Geneva – Unitaid is delighted to present its latest annual report, which charts the continuation of the organisation’s groundbreaking work, despite the immense challenges posed by the COVID-19 pandemic.
In this interactive report of our work from July 2019 to July 2020, you will find the reflections of our Executive Board Chair Marisol Touraine on the impact of COVID-19 on progress in HIV/AIDS, malaria and TB, and the thoughts of Executive Director Philippe Duneton on the role of Unitaid in defeating the pandemic.
COVID-19 presents a complex global health challenge, and Unitaid’s flexible model has enabled us to move quickly to make best use of existing partnerships and projects to aid the fight against the pandemic in low and middle-income countries.
In 2020, we joined global health actors and private sector partners in the Access to COVID Tools Accelerator to push forward the development, production and access to new COVID-19 diagnostics, treatments and vaccines. Unitaid co-convenes the Therapeutics Partnership, together with the Wellcome Trust, and co-leads the market-preparedness work stream in the Diagnostics Partnership.
Against this backdrop, we have continued to support crucial innovations in the fields of cervical cancer, HIV self-testing, anti-malaria nets and TB prevention, highlights of an impressive and expanding portfolio that aims to accelerate innovation to tackle the three diseases and co-infections. Our new agility mechanism, UnitaidExplore, was also launched in early 2020.
As we look to 2021 and beyond, the achievements outlined in this report reflect a great deal of progress despite the difficulties of 2020, and sets out a clear pathway for our work as an organisation.
Unitaid presents its annual report for 2019-20, which charts our key role in fighting #COVID19 as part of the #ACTAccelerator, as well as our continued investment in groundbreaking #innovations in #HIV, #TB, #malaria and co-infections. Read it here: https://t.co/iv3FFJUeYm pic.twitter.com/HrCjIaf8zI
— Unitaid (@UNITAID) December 10, 2020
Media contact:
